Fund manager flags ASX 200 heavyweight James Hardie as a buy after €840 million Fermacell sale plan
James Hardie's planned €840m sale of its European Fermacell unit to Holcim and the intended closure of its European fibre cement business signal a strategic pivot toward core North American growth and balance sheet deleveraging. Management's FY27 guidance upgrade (higher sales/EBITDA and ≥$500m free cash flow) supports a constructive company-specific read-through, but broader market impact is limited and largely idiosyncratic.
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Fund managers are bullish on ASX 200 constituent James Hardie Industries. The company plans to sell its European Fermacell business to Holcim for €840 million, and lifted its full-year outlook on that basis. James Hardie forecasts FY27 total net sales of $5.564 billion to $5.723 billion, adjusted EBITDA of $1.536 billion to $1.625 billion, and free cash flow of at least $500 million.